The masses have long tried to emulate legendary investors in the hopes of capturing some of their returns. Copy trading, also ...

Operator: Good afternoon, ladies and gentlemen, and welcome to the CytoSorbents Corp. Third Quarter 2025 Earnings Conference ...

Get key Q3 2025 earnings call insights on Cytosorbents (CTSO): growth drivers, FDA progress, cost controls, and outlook.

The MarketWatch News Department was not involved in the creation of this content.-- Third quarter 2025 revenue of $9.5 million, up 10% year-over-year -- Amended credit agreement w ...

Emerging technology stocks like Archer Aviation are prone to sharp price swings, and last week's turbulence came amid a ...

Just a few years ago, AI took the world by storm. It reshaped industries and minted fortunes for investors who saw the trend ...

Operating as an investment proxy for the cryptocurrency market, Strategy ($MSTR) represents a highly “popular” enterprise in ...

Though Nvidia and Palantir are Wall Street's AI darlings, a "magnificent" stock that's lurking in plain sight is far more ...

Embedded tax platform april—with partner Nasdaq Private Market—is launching real-time tax estimation to equity trading, ...

ATRN-119 is being evaluated in the open-label Phase 1/2a clinical trial (ABOYA-119) as monotherapy in patients with advanced solid tumors having at least one mutation in a defined panel of DDR-related ...

Third quarter 2025 revenue of $9.5 million, up 10% year-over-year Amended credit agreement with Avenue Capital Group which strengthens our balance sheet with ...